Digital Diagnostics

Digital Diagnostics is a leader in autonomous AI diagnostics, holding the historic first FDA clearance for an AI system that autonomously diagnoses diabetic retinopathy. The company's core technology, LumineticsCore, is a reimbursable, 30-second diagnostic tool deployed in primary care settings to close the significant care gap in annual diabetic eye exams. By enabling diagnosis outside of specialty clinics, Digital Diagnostics aims to prevent vision loss, improve healthcare efficiency, and address systemic health disparities. The company is generating real-world evidence through commercial deployments and is positioned to expand its platform into new diagnostic areas.

Autonomous Artificial Intelligence (AI) diagnostic platform for analyzing medical images and providing definitive diagnoses without clinician interpretation, with a focus on algorithmic fairness and EHR integration.

Digital Diagnostics competes in the broader AI diagnostics market, which includes large players like Google Health (assistive AI for DR), and numerous specialized startups. Its primary differentiator is its regulatory status as an *autonomous* AI, a category it pioneered. Competitors typically offer assistive tools that require clinician over-read. Other competitors include traditional telemedicine reading networks and in-person specialist referrals, which the company aims to displace or augment in primary care settings.